Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Provided By PR Newswire
Last update: Nov 13, 2024
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions
Read more at prnewswire.com
